Indeed, the antagonists Olmesartan and Irbesartan were found to increase the levels of EPCs (Dil-acLDL+ FITC‐UEA‐I+) in T2DM patients after 4 and 12 weeks of treatment [208], while the angiotensin-2 receptor blocker valsartan increased the levels of CD14+ KDR+ cells in DM patients with asymptomatic CAD [209]. Here, CD14 is linked to type 2 diabetes mellitus.